共 67 条
[1]
Faul MM(2003)Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta Bioorg Med Chem Lett 13 1857-1859
[2]
Gillig JR(2005)The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462-7469
[3]
Jirousek MR(1999)Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis Cancer Res 59 4413-4418
[4]
Graff JR(2006)Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer Histopathology 49 429-431
[5]
McNulty AM(1997)Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells Cell Growth Differ 8 381-392
[6]
Hanna KR(2006)Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts [abstract] Proc Am Assoc Cancer Res 47 1332-4099
[7]
Yoshiji H(2006)Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 24 4092-1141
[8]
Kuriyama S(2008)Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer J Clin Oncol 26 1135-1966
[9]
Ways DK(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-132
[10]
Lahn M(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-215